Improving clinical trial execution through data insights

• Leveraging data to inform early protocol design and feasibility
• Identifying optimal countries and investigator networks through data-led geographic analysis
• Benchmarking expected timelines, enrollment performance and cost parameters
• Enhancing site selection and feasibility assessment using integrated datasets and e-feasibility tools
• Applying real-time data monitoring to detect risks and inform mid-trial decision-making

 

Balancing in-house expertise and outsourcing for trial success

  • Comparing in-house and outsourced models for clinical trial execution
  • Evaluating decision-making frameworks for choosing the right resourcing strategy
  • Identifying key benefits and trade-offs in quality, speed, and flexibility
  • Exploring hybrid models and integrating CROs or FSPs effectively
  • Adapting operational approaches based on trial complexity, indication, and geography

PANEL DISCUSSION Comparing the all-in-one CRO model to specialized CRO models in clinical development

  • Analyzing the efficiency and cost benefits of an all-in-one CRO versus using specialized CROs for different phases
  • Evaluating the flexibility of a multi-CRO model in adapting to diverse project needs and expertise
  • Weighing the risks of relying on a single provider versus the coordination challenges of managing multiple vendors
  • Considering the impact on communication, data integration, and consistency when using a single CRO compared to multiple CROs
  • Discussing the potential for innovation and quality improvements with specialized CROs versus the streamlined approach of an all-in-one model

Moderator

Marie Rasoanandrasana, Head, Supply Chain and Vendor Management, Debiopharm

PANEL DISCUSSION Exploring shifting clinical trial landscapes and risk strategies

  • Exploring how geopolitics influences clinical trials, from trade policies to international relations
  • Discussing the impact of political changes and potential policy shifts
  • Analyzing regulatory landscapes and incentives in alternative regions
  • Addressing risk factors and strategic decision-making for trial site selection
  • Examining the role of ERCs and strategy departments in navigating global shifts
Moderator

Mara Hummel, Associate Director of Global Clinical Operations, Team Leader, Roche